Drugs / buthionine sulfoximine
buthionine sulfoximine
also known as
BSO · Buthionine sulfoxamine · Butionine sulfoximine · Dl-buthionine (s,r)-sulfoximine · L-buthionine(s,r)-sulfoximine · NSC-381100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00661336 | Apr 2008 → Dec 2009 | cutaneous melanoma | Duke University | Withdrawn | No outcome recorded |
| Phase 1 | NCT00005835 | Aug 2001 → Dec 2014 | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Completed | No outcome recorded |
| Phase 1 | NCT00002730 | Jun 1996 → ? | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | buthionine sulfoximine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002730 ↗ |
| Known as | BSO | “buthionine sulfoximine (BSO) IV continuously on days 1-3” NCT00661336 ↗1“BSO Buthionine sulfoximine” NCT00002730 ↗ |
| Known as | Buthionine sulfoxamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1256575 ↗ |
| Known as | Butionine sulfoximine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1256575 ↗ |
| Known as | Dl-buthionine (s,r)-sulfoximine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1256575 ↗ |
| Known as | L-buthionine(s,r)-sulfoximine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1256575 ↗ |
| Known as | NSC-381100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1256575 ↗ |
| Modality | Small molecule | — CHEMBL1256575 ↗ |
| Route | Intravenous | “Patients receive buthionine sulfoximine IV as a bolus over 30 minutes followed by a 72-hour continuous infusion beginning on day -4” NCT00005835 ↗ |